Pharvaris to Present at the GA²LEN UCARE Conference 2023
30 November 2023 - 10:50PM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin B2 receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced the acceptance
of one abstract for oral presentation and two abstracts for poster
presentation at the GA²LEN UCARE Conference 2023, to be held from
December 7-9, 2023, at the Rebouças Convention Center in São Paulo,
Brazil.
Presentation details:
- Title: Treatment of HAE Attacks with
Deucrictibant: RAPIDe-1 Phase2 Trial
ResultsPresenter: Markus Magerl,
M.D.Date/Time: Friday, December 8, 11:18-11:26
a.m. BST (9:18-9:26 a.m. EST)Presentation Code:
O07Type: Oral Presentation
- Title: Analyzing Symptom Relief Definitions in
HAE Using AMRA and PGI-C/PGI-SPresenter: Danny M.
Cohn, M.D.Date/Time: Friday, December 8, 7:00-8:00
p.m. BST (5:00-6:00 p.m. EST)Presentation Code:
P080Type: Happy Poster Hour Presentation
- Title: Early-Onset Response to Treatment of
Hereditary Angioedema Attacks with
DeucrictibantPresenter: Marcus Maurer,
M.D.Date/Time: Friday, December 8, 7:00-8:00 p.m.
BST (5:00-6:00 p.m. EST)Presentation Code:
P081Type: Happy Poster Hour Presentation
Pharvaris is a bronze level sponsor of the GA²LEN UCARE
Conference 2023. Following the close of the respective sessions,
the presentation slides and posters will be made available on the
Investors section of the Pharvaris website
at: https://ir.pharvaris.com/news-events/events-presentations.
About PharvarisBuilding on its deep-seated
roots in HAE, Pharvaris is a clinical-stage company developing
novel, oral bradykinin B2 receptor antagonists to treat and prevent
HAE attacks. By directly pursuing this clinically proven
therapeutic target with novel small molecules, the Pharvaris team
aspires to offer people with all sub-types of HAE efficacious,
safe, and easy-to-administer alternatives to treat attacks, both
on-demand and prophylactically. The company brings together the
best talent in the industry with deep expertise in rare diseases
and HAE. For more information, visit https://pharvaris.com/.
Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
maggie.beller@pharvaris.com
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Jan 2024 to Jan 2025